title: Effect of dietary tetradecylthioacetic acid on colon cancer growth studied by dynamic contrast enhanced MRI.
abstract: OBJECTIVE
  To evaluate the effects of diets supplemented with the modified fatty acid tetradecylthioacetic acid (TTA) and fish protein hydrolysate (FPH) on tumor growth of the human colon cancer cell line SW620, and to investigate the properties of tumor vasculature by dynamic contrast-enhanced MRI in a human tumor xenograft.
  
  
  METHODS
  SW620 cells were grown in vitro in presence of TTA and palmitic acid and proliferation was measured by thymidine incorporation. The xenograft study in mice was performed with four distinct diets: (a) control diet; (b) diet with TTA; (c) diet with TTA and FPH; and (d) diet with FPH. SW620 cells were injected subcutaneously, and dynamic contrast enhanced (DCE) MRI was performed on a Bruker BioSpec 7T system. The data was analyzed by two-compartment modeling of the contrast enhancement, initial area under the curve (IAUC) and by use of relative signal intensity (RSI) distributions.
  
  
  RESULTS
  The in vitro cell studies revealed that TTA reduced tumor cell proliferation as a function of both dose and time. The in vivo tumor growth was significantly reduced for the two groups fed TTA, as compared to the control group. The mean 10(th) percentile RSI, v(e) and IAUC for the TTA group were significant higher than for the control group.
  
  
  CONCLUSIONS
  This study confirms the growth inhibitory effects of TTA, both in vitro and in vivo, in a colon cancer model. The analysis of DCE-MRI data showed that TTA influences the vascular properties of the tumor in addition to the growth.
authors.affiliation: Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. line.r.jensen@ntnu.no
authors.forename: Line R
authors.initials: LR
authors.lastname: Jensen
authors.forename: Kjetil
authors.initials: K
authors.lastname: Berge
authors.forename: Tone F
authors.initials: TF
authors.lastname: Bathen
authors.forename: Hege
authors.initials: H
authors.lastname: Wergedahl
authors.forename: Svanhild A
authors.initials: SA
authors.lastname: Schønberg
authors.forename: Anna
authors.initials: A
authors.lastname: Bofin
authors.forename: Rolf K
authors.initials: RK
authors.lastname: Berge
authors.forename: Ingrid S
authors.initials: IS
authors.lastname: Gribbestad
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D019587:Dietary Supplements; D005260:Female; D029941:Fish Proteins / Q000008:administration & dosage; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D008807:Mice, Inbred BALB C; D013440:Sulfides / Q000008:administration & dosage*; D023041:Xenograft Model Antitumor Assays
chemical_list: D029941:Fish Proteins; D013440:Sulfides; C062078:1-(carboxymethylthio)tetradecane